Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersMedical Oncology Physician in Baltimore, MD
NPI: 1265758601Primary Practice Location
JOHNS HOPKINS BAYVIEW MEDICAL CENTER
4940 Eastern Ave, Baltimore, MD
Primary Employer
Jhu - Oncology
hopkinsmedicine.org
HQ Phone
Get M.D. Vincent's Phone Numberphone_androidMobile
Get M.D. Vincent's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardMD State Medical License
TX State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 85 | 173 |
| 2 | 99205New patient office or other outpatient visit, typically 60 minutes | 27 | 27 |
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity.
Authors: Yasir Elamin, George Blumenschein, Anisha Patel, Mark Routbort, Charles Lu, Frank Fossella, Anne Tsao, Anisha Patel, Brett Carter, Lauren Byers, Xiuning Le, Jianjun Zhang, John Heymach, Marcelo Vailati Negrao, Tina Cascone, Mehmet Altan
Publication Date: 2022-07
Longitudinal Tracking of ALK-Rearranged NSCLC From Plasma Using Circulating Tumor RNA and Circulating Tumor DNA.
Authors: Yasir Elamin, George Blumenschein, Mara Antonoff, Anne Tsao, Carl Gay, John Heymach, Tina Cascone, Mehmet Altan
Publication Date: 2024-07-11
Lead Sponsor: M.D. Anderson Cancer Center
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Brigatinib, PROCEDURE: Local Consolidation Therapy
Lead Sponsor: GlaxoSmithKline
Collaborators: Merck Sharp & Dohme LLC
Intervention / Treatment: DRUG: Pembrolizumab, DRUG: Lete-cel
Lead Sponsor: Seagen Inc.
Intervention / Treatment: DRUG: brentuximab vedotin, DRUG: SEA-TGT, DRUG: sasanlimab
